Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy (Q45353928)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 November 2012

Language	Label	Description	Also known as
English	Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy	scientific article published on 15 November 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

based on heuristic

inferred from title

Hepatitis B virus

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yin-Hua Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Lei Fan

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Li Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Run Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Ji Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Cheng Fang

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Jian-Yong Li

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Wei Xu

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

publication date

15 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Supportive Care in Cancer

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1265-1271

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Prevention and control of hepatitis B in China

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1656-8

21 January 2018

Rituximab treatment results in impaired secondary humoral immune responsiveness.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/23151650

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-012-1656-8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45353928&oldid=2207221519"